Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4)
Disc Medicine (NASDAQ:IRON) has announced an inducement equity award for a new employee, effective January 16, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Disc Medicine (NASDAQ:IRON) has announced an inducement equity award for a new employee, effective January 16, 2025. The award consists of two components: (1) an option to purchase 35,000 shares of common stock at the January 16, 2025 closing price, and (2) a restricted stock unit (RSU) award for 23,333 shares.
The stock option has a ten-year term with 25% vesting on January 16, 2026, and the remaining vesting monthly over 36 months. The RSU award vests in equal installments over four years. The Compensation Committee approved this award as an employment inducement under Nasdaq Rule 5635(c)(4), outside the company's regular stock incentive plan but under similar terms.
Details
News Market Reaction – IRON
The recorded move for IRON in the trading session of this news was +3.91%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the grant of an inducement equity award to a new employee, effective January 16, 2025.
The inducement award is comprised of (i) an option to purchase 35,000 shares of Disc’s common stock, at an exercise price equal to the closing price of Disc’s common stock on January 16, 2025, and (ii) a restricted stock unit (RSU) award for 23,333 shares of Disc’s common stock. The stock option has a ten-year term and will vest as to
The inducement award was approved by the Compensation Committee of Disc’s Board of Directors and was made as an inducement material to the employee entering into employment with Disc in accordance with Nasdaq Listing Rule 5635(c)(4). While the inducement award was granted outside of Disc’s Amended and Restated 2021 Stock Option and Incentive Plan, the award is subject to terms and conditions substantially consistent with those set forth under such plan.
About Disc Medicine
Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.
Media Contact
Peg Rusconi
Deerfield Group
peg.rusconi@deerfieldgroup.com
Investor Relations Contact
Christina Tartaglia
Precision AQ
christina.tartaglia@precisionaq.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.